Chronic myeloid leukemia from basics to bedside.
The discovery of the Philadelphia chromosome and its consistent involvement in chronic myeloid leukemia (CML) was the first time that a relationship between a cytogenetic abnormality and malignancy was demonstrated. This review will try to provide an insight into the molecular mechanisms underlying this disease and outline the therapeutical options for patients with CML.
Thijsen
S
S
Department of Hematology, Br 250, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Schuurhuis
G
G
van Oostveen
J
J
Ossenkoppele
G
G
D016465:Bone Marrow Purging; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D020732:Cytogenetic Analysis; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000276:immunology; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy; D010677:Philadelphia Chromosome; D015398:Signal Transduction / Q000235:genetics
D016044:Fusion Proteins, bcr-abl